Aquestive Therapeutics Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 36.9% | 35.4% | 36.4% | 22.5% | 32.8% | 38.1% | 41.9% | 45.6% | 35.2% | 44.8% | 24.0% | 29.1% | 33.0% | |
| 63.1% | 64.6% | 63.6% | 77.5% | 67.2% | 61.9% | 58.1% | 54.4% | 64.8% | 55.2% | 76.0% | 70.9% | 67.0% | |
| 24.6% | 21.9% | 49.2% | 20.7% | 38.9% | 41.4% | 61.5% | 41.0% | 35.4% | 24.6% | 29.1% | 28.7% | 29.4% | |
| 56.8% | 72.3% | 88.7% | 56.5% | 89.5% | 134.9% | 218.7% | 127.0% | 119.1% | 252.2% | 76.0% | 86.0% | 131.2% | |
| 81.4% | 94.2% | 137.9% | 77.2% | 128.5% | 176.3% | 280.2% | 168.0% | 154.4% | 276.7% | 105.1% | 130.4% | 164.6% | |
| -18.3% | -29.6% | -74.3% | 0.3% | -61.2% | -114.4% | -222.1% | -113.6% | -89.6% | -221.6% | -29.1% | -59.5% | -97.5% | |
| 10.1% | 24.5% | 34.8% | 20.9% | 31.0% | 35.6% | 49.1% | 42.7% | 33.4% | 32.8% | 27.2% | 27.8% | 30.2% | |
| -16.7% | -60.7% | -106.4% | -13.7% | -85.0% | -143.8% | -263.0% | -135.4% | -120.6% | -244.8% | -55.8% | -165.5% | -144.6% | |
| -1.1% | 0.8% | 1.4% | – | – | -0.1% | – | – | – | – | – | – | – | |
| -15.7% | -61.4% | -106.4% | -13.7% | -85.0% | -143.7% | -263.0% | -135.4% | -120.6% | -244.8% | -55.8% | -165.5% | -144.6% | |
| -4.7% | -32.6% | -69.9% | 8.2% | -52.8% | -107.0% | -212.3% | -91.3% | -86.2% | -211.0% | -27.7% | -135.9% | -113.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.